multicenter, USA - 19 Mar `18Aclaris Therapeutics: Topical Solution

Official title: An Open-Label Pilot Study of the Safety, Tolerability and Efficacy of ATI-50002 Topical Solution Administered Twice-Daily in Adult Subjects With Non-Segmental Facial Vitiligo

In brief: This is a multicenter, open-label study designed to evaluate the safety, tolerability and efficacy of ATI-50002 Topical Solution 0.46% in subjects with non-segmental facial vitiligo. Subjects will be required to have a clinical diagnosis of non-segmental facial vitiligo effecting at least 0.25% of total body surface area (TBSA) (excluding upper and lower eyelids, mucosal lip areas, and forehead and chin areas covered by the stereotactic positioning device for photography) with at least one area of the face with normal pigmentation. Twenty-four eligible subjects will receive ATI-50002 Topical Solution, 0.46%, BID for 24 weeks.

Ages eligible: 18 Years to 65 Years

Locations: Aclaris Investigator Site 

  • Encinitas, California, United States, 92024
  • Los Angeles, California, United States, 90036
  • Worcester, Massachusetts, United States, 01655
  • Dallas, Texas, United States, 75390
  • Lynchburg, Virginia, United States, 24501

Status: Unknown, not recruiting

Start date: March 19, 2018
Completion date: September 30, 2019

Identifier: NCT03468855

Contacts: To learn more about this study, you or your doctor may contact Aclaris Therapeuitcs. Please refer to this study by its NCT number.

FAQOther Questions

  • I have vitiligo: will my children have vitiligo, too?

    Children born to parents who both have the disorder are more likely to develop vitiligo. However, most children will not get vitiligo even if one parent has it. In children wit...

  • Will it spread?

    Vitiligo activity may vary considerably from person to person. In a good number of patients the disease goes on for 3-4 years and then it settles down, with one or two stubborn...

  • Who is prone to vitiligo?

    Scientists know that some people are genetically predisposed to a specific group of autoimmune diseases – including generalized vitiligo – but do not know who and why.It doesn’t...